Detailed analysis of cumulative incidence for GvHD grade III/IV, gastrointestinal GvHD stage II/IV, and TRM at one year in relation to donor and recipient NOD2/CARD15 mutations
. | Cumulative incidence, % . | 95% CI for cumulative incidence, % . | P . | Hazard ratio . | 95% CI for hazard ratio . |
|---|---|---|---|---|---|
| GvHD III/IV | |||||
| Wild type | 19 | 13-27 | 1.0 | ||
| R pos | 36 | 21-61 | .07 | 2.1 | (0.9-4.7) |
| D pos | 44 | 25-76 | .02 | 2.8 | (1.2-6.5) |
| R&D pos | 58 | 36-94 | .002 | 3.9 | (1.7-9.2) |
| GI GvHD | |||||
| Wild type | 18 | 12-27 | 1.0 | ||
| R pos | 36 | 21-63 | .07 | 2.1 | (0.9-4.8) |
| D pos | 31 | 15-65 | .16 | 2.0 | (0.8-5.3) |
| R&D pos | 56 | 36-94 | .001 | 4.3 | (1.8-10.1) |
| 1-year TRM | |||||
| Wild type | 20 | 14-29 | 1.0 | ||
| R pos | 49 | 31-76 | .03 | 2.2 | (1.1-4.6) |
| D pos | 59 | 38-91 | .004 | 3.1 | (1.4-6.5) |
| R&D pos | 83 | 65-100 | .001 | 3.9 | (1.7-8.6) |
. | Cumulative incidence, % . | 95% CI for cumulative incidence, % . | P . | Hazard ratio . | 95% CI for hazard ratio . |
|---|---|---|---|---|---|
| GvHD III/IV | |||||
| Wild type | 19 | 13-27 | 1.0 | ||
| R pos | 36 | 21-61 | .07 | 2.1 | (0.9-4.7) |
| D pos | 44 | 25-76 | .02 | 2.8 | (1.2-6.5) |
| R&D pos | 58 | 36-94 | .002 | 3.9 | (1.7-9.2) |
| GI GvHD | |||||
| Wild type | 18 | 12-27 | 1.0 | ||
| R pos | 36 | 21-63 | .07 | 2.1 | (0.9-4.8) |
| D pos | 31 | 15-65 | .16 | 2.0 | (0.8-5.3) |
| R&D pos | 56 | 36-94 | .001 | 4.3 | (1.8-10.1) |
| 1-year TRM | |||||
| Wild type | 20 | 14-29 | 1.0 | ||
| R pos | 49 | 31-76 | .03 | 2.2 | (1.1-4.6) |
| D pos | 59 | 38-91 | .004 | 3.1 | (1.4-6.5) |
| R&D pos | 83 | 65-100 | .001 | 3.9 | (1.7-8.6) |
Wild type indicates donor and recipient unmutated (n = 119); R pos, mutations in recipients only (n = 22); D pos, mutations in donors only (n = 16); R&D pos, mutations of both recipient and donor (n = 12). Comparison between groups was performed by Cox regression analysis. For each group, significance and hazard ratios are given.